Losses at Inspire (Nasdaq: ISPH) climbed in the second quarter as the company increased marketing and sales costs to promote the drugs Restasis and Elestat.
Inspire produced $2.9 million in sales for the quarter and deferred another $700,000. The sales income was less than the $4.1 million received in the same time frame a year ago for research and development.
Overall, Inspire’s costs increased to $12.8 million, and the company’s losses increased to $6.6 million, or 21 cents a share.
The company’s income did not include the $77 million produced through a stock offering of 6.9 million shares.
Inspire: www.inspirepharm.com
